In exclusive clinical partnership with KPCIRC
OnKommon
Get Started
  1. Home
  2. Signature
  3. Signature STb

Signature · fast, focused, actionable

Signature STb

33 uniquely actionable genes and 13 fusion genes from a simple blood draw, mapped only to drugs accessible in India today.

Book a free consultation

01When time is the critical asset

Fast, focused, actionable

You cannot always wait weeks for a large report. Signature STb is a high-speed liquid biopsy across 33 uniquely actionable genes.

It strips away the noise and looks only at drivers and fusions that have targeted therapies approved and accessible in India today.

33actionable genes
13fusion genes
1blood draw
Image placeholder

A home blood draw, handled for you

What goes here: Photograph of a qualified phlebotomist taking a blood sample in a patient’s home. Calm, unhurried, clean technique visible. Include the collection kit in frame so the logistics feel real and professional. Avoid anything that looks like a self-test kit, because these kits are for phlebotomists only.

02

Why choose it

Urgent turnaround

When your doctor needs an answer now to start first or second-line treatment.

Fully actionable

Every gene has a real-world option attached, so a positive result means something.

Non-invasive

A blood draw gives answers without waiting for surgery.

03Every gene on this test

The panel

33 genes on the panel

SNVs and InDels

33 genes

High-depth analysis across the actionable driver genes.

  • AKT1
  • ALK
  • ATM
  • BRAF
  • CDKN2A
  • CTNNB1
  • DDR1
  • DDR2
  • EGFR
  • ERBB2
  • ERBB3
  • ERBB4
  • FGFR1
  • FGFR2
  • FGFR3
  • FGFR4
  • HRAS
  • KIT
  • KRAS
  • MAP2K1
  • MET
  • NRAS
  • NRG1
  • NTRK1
  • NTRK2
  • NTRK3
  • PIK3CA
  • PTEN
  • PTPN11
  • RET
  • ROS1
  • SMAD4
  • TP53

Fusion genes

13 genes

Rearrangements with clinically actionable targets.

  • ALK
  • BRAF
  • FGFR1
  • FGFR2
  • FGFR3
  • FGFR4
  • MET
  • NRG1
  • NTRK1
  • NTRK2
  • NTRK3
  • RET
  • ROS1

Every gene here has a directly approved drug or an accessible clinical trial in India. The 13 fusion genes are also within the 33.

04

Also included

  • The 35-gene pharmacogenomics panel, plus MSI and MMR status.
  • TMB and MSI via an adhoc 200+ gene test, so this focused panel still delivers the key immune markers.
  • A tumour-fraction estimate.

05

What your oncologist gets back

Immediate drug matching

Detected mutations mapped to targeted therapies accessible in India today.

Biosimilar mapping

Expensive therapies paired with clinically equivalent, CDSCO-approved biosimilars.

Resistance flagging

Variants that cause resistance to standard therapies, so your doctor can pivot.

06

How the test is done

  1. Step 1Urgent sample collection

    A blood draw by a qualified phlebotomist, at home or in clinic.

  2. Step 2Rapid sequencing

    Cell-free DNA extracted and sequenced on a fast-tracked pipeline.

  3. Step 3Actionable translation

    The engine maps targets to drugs accessible in India.

  4. Step 4Sign-out and delivery

    A medical oncologist signs off and your navigator executes.

07

Price and limits

₹1,50,000 panel plus execution bundle

Includes the testing panel, the Blueprint Care decision report with three months of care coordination, and an in-person KPCIRC molecular tumour board review.

If a mutation is found, your care coordinator steps in immediately: logistics, assistance programme paperwork, and working with your doctor to secure medication.

  • Test boundaries. A normal result means the tumour does not carry these 33 mutations. It does not mean the cancer is gone, and it does not cover the other roughly 20,000 genes in the body.
  • DNA shedding. Not all cancers release enough DNA into blood to be detected.
  • Clonal haematopoiesis. Occasionally, detected changes come from normal ageing blood cells rather than the tumour.

Research and evidence

The science behind this

Focused, blood-based genotyping to guide immediate therapy is supported by liquid-biopsy evidence.

Study 1

Plasma genotyping finds more targets

Adding plasma ctDNA testing to tissue in advanced lung cancer increased detection of targetable alterations and the number of patients who received matched therapy.

Aggarwal C, et al. JAMA Oncology, 2019.

Study 2

Blood-based profiling, extensively validated

A cfDNA comprehensive genomic profiling assay was validated across more than 7,500 tests and over 30,000 variants, spanning 300+ genes and 30+ cancer types.

Woodhouse R, et al. PLoS ONE, 2020.

These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.

Being clear about our limits

What we do and do not do

What we DO

  • Find directly actionable drivers and fusions, fast
  • Include an immune profile and pharmacogenomics
  • Map targets to India-accessible drugs and biosimilars
  • Flag resistance variants so your team can pivot

What we DON’T do

  • Diagnose cancer or decide treatment alone
  • Report broad copy-number changes
  • Rule out disease from a normal result
  • Guarantee a drug’s availability, approval, cover or benefit
Plain-language glossary (9 terms)
TermWhat it means
ctDNACirculating tumour DNA, tumour fragments in blood that a liquid biopsy reads.
SNV / InDelA single-letter DNA change, or a small insertion or deletion.
FusionTwo genes joined abnormally, creating a driver that is often highly treatable.
CNVCopy-number variation, extra or missing copies of a gene.
TMBTumour mutational burden, how many mutations a tumour carries.
MSI / MMRSignals of faulty DNA repair that often predict immunotherapy response.
PGxPharmacogenomics, how your genes affect the way you handle specific drugs.
Tumour fractionHow much of the blood DNA came from the tumour.
CCRComplete coding region, meaning the whole gene is read rather than known hotspots.
Important information and regulatory status

Signature STb is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.

  • A result is not a diagnosis and does not by itself decide treatment.
  • A “not detected” result does not rule out cancer or a genetic change.
  • Not all cancers release enough DNA into blood to be detected.
  • We cannot guarantee that a medicine will be available, approved, covered or effective.
  • Collection kits are for qualified phlebotomists. They are not for self-testing.
  • Confirmatory testing may be required.

Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Take the next step

Three ways forward. Pick the one that fits today.

01

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation
02

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care
03

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal